Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
MB-PD-101
- Development stage
- Preclinical
- Lead developer
- Mercury Bio
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
MB-PD-101 is an intracellular immunotherapeutic nanobody currently in preclinical development by Mercury Bio for the treatment of Parkinson's disease. The therapeutic is designed to be delivered across the blood-brain barrier and into neurons using Mercury Bio's specialized delivery platform. Once internalized, the nanobody targets and modulates intracellular pathogenic proteins that contribute to the neurodegenerative process in Parkinson's disease. By targeting these proteins directly within the cell, MB-PD-101 aims to provide a more precise and effective intervention than traditional extracellular therapies.
Beyond the preview
Go deeper on MB-PD-101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on MB-PD-101.